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Abstract
Defective FUS metabolism is strongly associated with amyotrophic
lateral sclerosis and frontotemporal dementia (ALS/FTD), but the
mechanisms linking FUS to disease are not properly understood.
However, many of the functions disrupted in ALS/FTD are regulated
by signalling between the endoplasmic reticulum (ER) and mito-
chondria. This signalling is facilitated by close physical associations
between the two organelles that are mediated by binding of the
integral ER protein VAPB to the outer mitochondrial membrane
protein PTPIP51, which act as molecular scaffolds to tether the
two organelles. Here, we show that FUS disrupts the VAPB–PTPIP51
interaction and ER–mitochondria associations. These disruptions
are accompanied by perturbation of Ca2+ uptake by mitochondria
following its release from ER stores, which is a physiological
read-out of ER–mitochondria contacts. We also demonstrate that
mitochondrial ATP production is impaired in FUS-expressing cells;
mitochondrial ATP production is linked to Ca2+ levels. Finally, we
demonstrate that the FUS-induced reductions to ER–mitochondria
associations and are linked to activation of glycogen synthase
kinase-3b (GSK-3b), a kinase already strongly associated with ALS/
FTD.
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Introduction
Mitochondria and the endoplasmic reticulum (ER) form tight struc-
tural associations such that ~5–20% of the mitochondrial surface is
closely apposed (10–30 nm distances) to specialized regions of the
ER termed mitochondria-associated ER membranes (MAM) [1–3].
These associations regulate a number of fundamental physiological
functions including Ca2+ and phospholipid exchange between the
two organelles, energy metabolism and ATP production, mitochon-
drial biogenesis and trafficking, apoptosis, ER stress responses and
autophagy [1–3]. The mechanisms by which MAM become associ-
ated with mitochondria are not properly understood but electron
microscopy (EM) studies reveal the presence of structures that
appear to tether the two organelles [4]. Recently, the integral ER
protein, vesicle-associated membrane protein-associated protein B
(VAPB), was shown to bind to the outer mitochondrial membrane
protein, protein tyrosine phosphatase interacting protein 51
(PTPIP51), to form at least some of these tethers [5,6]. Thus, modu-
lating VAPB and/or PTPIP51 expression induces appropriate
changes in ER–mitochondria contacts and also Ca2+ exchange
between the two organelles, which is a physiological read-out of
ER–mitochondria contacts [5,6].
Many of the functions regulated by ER–mitochondria contacts
are perturbed in ALS and associated FTD. ALS is the most common
form of motor neuron disease, and FTD is the second most common
form of presenile dementia after Alzheimer’s disease [7]. These
diseases are now known to be clinically, genetically and pathologi-
cally linked [7,8]. Thus, damage to mitochondria, ATP production,
Ca2+ homoeostasis, lipid metabolism, axonal transport, autophagy
and the ER including activation of the unfolded protein response
(UPR) are all features of ALS/FTD, and ER–mitochondria communi-
cations impact upon all of these processes [1–3,9,10]. Indeed, recent
studies have demonstrated that some ALS/FTD-associated insults
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disrupt ER–mitochondria contacts and associated functions. These
include the expression of Tar DNA-binding protein-43 (TDP-43) and
loss of Sigma-1 receptor (Sigma-R1) function [6,11]. Mutations in
both TDP-43 and Sigma-R1 cause some familial forms of ALS/FTD
and accumulations of TDP-43 are a major pathology of ALS/FTD
[12–16].
Defects in fused in sarcoma (FUS) metabolism are strongly impli-
cated in both ALS and FTD. FUS accumulations are a pathological
feature in a significant number of ALS/FTD cases, mutations in FUS
cause some familial forms of ALS and FTD, and overexpression of
wild-type and ALS/FTD-mutant FUS induces aggressive disease in
transgenic rodents [7,17–27].
FUS is a predominantly nuclear protein where it functions in
DNA repair, transcription and splicing but a proportion is also
normally present in the cytoplasm [26,27]. However, the mecha-
nisms by which FUS induces disease are not clear and both gain and
loss of function hypotheses have been proposed [26,27]. Here, we
show that the expression of both wild-type and ALS-mutant FUS
disrupt ER–mitochondria associations and that this is accompanied
by reductions in binding of VAPB to PTPIP51. We also demon-
strate that FUS perturbs cellular Ca2+ homoeostasis and mitochon-
drial ATP production. Damage to mitochondria is strongly linked
to ALS [28–34]. Finally, we show that FUS activates glycogen
synthase kinase-3b (GSK-3b) and that GSK-3b is a regulator of
ER–mitochondria associations. GSK-3b is already strongly impli-
cated in ALS/FTD [6,35–37]. Thus, our findings reveal a new
pathogenic mechanism for FUS involving activation of GSK-3b and
disruption to ER–mitochondria associations.
Results
Wild-type and mutant FUS disrupt ER–mitochondria associations
and the VAPB–PTPIP51 interaction
To determine the effects of FUS on ER–mitochondria associations,
we quantified ER–mitochondria contacts in NSC34 motor neuron
cells transfected with either enhanced green fluorescent protein
(EGFP) control vector, EGFP-FUS or familial ALS mutants EGFP-
FUSR521C or EGFP-FUSR518K. Several previous studies have
utilized EGFP-tagged FUS [24,38] but to confirm that the EGFP-FUS
was functional, we monitored the expression of endogenous FUS
72 h post-transfection. FUS displays an autoregulatory function such
that overexpression by transfection reduces endogenous gene
expression [38]. At this time point, we detected a marked decrease
in endogenous FUS expression in both wild-type and mutant EGFP-
FUS-transfected cells (Fig EV1). These findings are in agreement
with previous studies, which also showed that the EGFP tag does
not affect the autoregulatory function of FUS [38].
The EGFP tags were then used to isolate transfected cells using a
cell sorter and ER–mitochondria associations quantified by deter-
mining the proportion of the mitochondrial surface that was closely
apposed (< 30 nm) to ER following analyses by EM. This approach
has been used previously [4,6,39]. Transfection of FUS did not lead
to changes in the expression of the ER–mitochondria tethering
proteins VAPB or PTPIP51, or mitofusin-2, which has been
proposed as a further ER–mitochondria tether [40] (Fig 1A). More-
over, we detected no change in the numbers of mitochondria or ER
profiles in the presence of either wild-type or mutant FUS. However,
compared to control cells, the expression of wild-type and mutant
FUS all led to significant reductions in ER–mitochondria associations
(Fig 1B).
We also enquired whether loss of FUS influenced ER–
mitochondria associations. To do so, we treated NSC34 cells with
control or FUS siRNAs and again monitored ER–mitochondria
associations by EM. siRNA knockdown of FUS did not alter the
expression of VAPB, PTPIP51 or mitofusin-2, and loss of FUS had
no effect on ER–mitochondria associations (Fig 1C and D).
To complement the EM studies, we monitored the effects of FUS
on ER–mitochondria associations using super resolution structured
illumination microscopy (SIM) [41]. NSC34 cells were again trans-
fected with EGFP control vector, EGFP-FUS, EGFP-FUSR521C or
EGFP-FUSR518K and then immunostained for protein disulphide
isomerase (PDI) and translocase of the outer mitochondrial
membrane protein-20 (TOM20) to label ER and mitochondria,
respectively. Co-localization analyses of PDI and TOM20 revealed
that wild-type and mutant FUS again disrupted ER–mitochondria
associations (Fig 2A).
Finally, we used in situ proximity ligation assays [42] to monitor
the effects of FUS on ER–mitochondria associations. Here, conven-
tionally fixed cells and tissues are probed with primary antibodies
followed by secondary antibodies coupled to specific oligo-
nucleotides. If the distances between antigens are small enough,
these oligonucleotides facilitate hybridization and ligation of
connector oligonucleotides to form a circular DNA molecule, which
then serves as a template for rolling circular amplification. Use of
labelled nucleotides enables microscopic detection and quan-
tification of hybridization signals. The distances detected by proxim-
ity ligation assays are similar to those detected by resonance energy
transfer between fluorophores (i.e. ~10 nm) [42]. For these assays,
we used antibodies to the ER protein VAPB and the outer mitochon-
drial membrane protein PTPIP51 since VAPB and PTPIP51 interact
directly to tether ER with mitochondria [5,6]. Proximity ligation
assays have already been used to quantify ER–mitochondria associa-
tions and the VAPB–PTPIP51 interaction [5,11,43].
To demonstrate the specificity of the proximity ligation assays,
we first performed experiments involving omission of VAPB,
PTPIP51 or both VAPB and PTPIP51 primary antibodies. In agree-
ment with previous studies [5], omission of VAPB and/or PTPIP51
antibodies produced very few signals whereas inclusion of these
primary antibodies generated robust signals (Fig EV2A). We then
monitored how FUS expression affected the VAPB–PTPIP51 interac-
tion. Compared to control EGFP, transfection of either wild-type or
mutant FUS did not affect the size of the cells (% size: EGFP
100  5.93, EGFP-FUS 96.86  4.57, EGFP-FUSR521C 102  5.3,
EGFP-FUSR518K 112.9  5.9; analysed by one-way ANOVA).
However, compared to controls, reduced interactions between VAPB
and PTPIP51 were detected in both wild-type and mutant FUS-
transfected NSC34 cells (Fig 2B). Thus, in three different assays,
wild-type and ALS/FTD-mutant FUS disrupt ER–mitochondria
associations.
As a complement to these cellular studies, we investigated
ER–mitochondria associations in spinal cord motor neurons of
10-week-old homozygous FUS transgenic mice and their non-
transgenic littermates [19]. These transgenic mice express wild-type
FUS under control of the commonly used mouse prion gene
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regulatory elements, which drive expression to a variety of neural
cell types including motor neurons [19]. The homozygous FUS
transgenic mice develop aggressive features of ALS including
hindlimb paralysis and death by 12 weeks of age [19]. Similar to
the findings in NSC34 cells, no changes in the expression of
VAPB, PTPIP51 or mitofusin-2 were detected in FUS transgenic
mice (Fig 3A). However, EM analyses revealed that compared to
non-transgenic control littermates, ER–mitochondria associations
were significantly reduced in spinal cord motor neurons of the
FUS transgenics (Fig 3B). We also utilized VAPB/PTPIP51
proximity ligation assays to quantify ER–mitochondria contacts in
spinal cord motor neurons of the FUS transgenic mice. Again, we
first tested the specificity of the assays by performing control
experiments in which VAPB, PTPIP51 or both VAPB and PTPIP51
primary antibodies were omitted and these revealed that omission
of primary antibodies produced very few signals but their inclu-
sion generated robust signals (Fig EV2B). Compared to control
non-transgenic littermates, we detected no differences in motor
neuron size in the FUS transgenics (% size: control 100  4.96,
FUS 95.65  5.32; analysed by unpaired t-test). However, the
A B
C D
Figure 1. Expression of wild-type and ALS/FTD-mutant FUS reduces ER–mitochondria associations in NSC34 cells.
A Expression of FUS does not alter expression of VAPB, PTPIP51 or mitofusin-2 (MFN2) in transfected NSC34 cells. Immunoblots of NSC34 cells transfected with EGFP
as a control (CTRL), or wild-type or mutant EGFP-FUS. Transfected cells were purified via EGFP using a cell sorter and the samples probed on immunoblots as
indicated. On the FUS immunoblot, samples were probed with FUS antibody to show endogenous and transfected proteins; tubulin is shown as a loading control.
B Representative electron micrographs of ER–mitochondria associations in NSC34 cells transfected with control EGFP vector (CTRL), EGFP-FUS, EGFP-FUSR521C or
EGFP-FUSR518K as indicated; arrowheads with loops show regions of association. Scale bar = 200 nm. Bar chart shows % of the mitochondrial surface closely
apposed to ER in the different samples. Data were analysed by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. N = 27–30 cells
and 247–424 mitochondria, error bars are s.e.m.; ***P < 0.001.
C, D siRNA loss of FUS does not affect ER–mitochondria associations or alter expression of VAPB, PTPIP51 or mitofusin-2 (MFN2) in NSC34 cells. (C) Immunoblots of
cells either mock transfected or treated with control (CTRL) or FUS siRNAs; GAPDH is shown as a loading control. (D) Representative electron micrographs of
ER–mitochondria associations in control (CTRL) and FUS siRNA-treated cells. Arrowheads with loops show regions of association. Scale bar = 200 nm. Data
analysed by unpaired t-test. N = 27–28 cells and 193–202 mitochondria, error bars are s.e.m.
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VAPB/PTPIP51 proximity ligation assays revealed that in agree-
ment with the EM analyses, ER–mitochondria associations were
significantly reduced in spinal cord motor neurons of the FUS
transgenics (Fig 3C).
Since we detected no FUS-induced changes in expression
of VAPB or PTPIP51 in either NSC34 cells or transgenic mice
(Figs 1A and C, and 3A), the proximity ligation assays not only
confirm that FUS reduces ER–mitochondria associations but also
show that this reduction involves breaking of the VAPB–PTPIP51
tethers. To test this further, we performed immunoprecipitation
assays to monitor the affect of FUS on binding of VAPB to PTPIP51.
To do so, we co-transfected cells with haemagglutinin (HA)-tagged
PTPIP51 and either EGFP control vector, EGFP-FUS, EGFP-
FUSR521C or EGFP-FUSR518K and monitored the amounts of VAPB
bound to immunoprecipitated PTPIP51-HA by immunoblotting of
the samples. Consistent with the proximity ligation assays, both
wild-type and mutant FUS decreased the amounts of endogenous
VAPB bound to immunoprecipitated PTPIP51-HA in these assays
(Fig 2C). Thus, the FUS-induced reductions in ER–mitochondria
associations involve decreased interactions between the tethering
proteins VAPB and PTPIP51.
Overexpression of FUS disturbs cellular Ca2+ homoeostasis and
mitochondrial ATP production
A major function of ER–mitochondria associations is to regulate
cellular Ca2+ homoeostasis and in particular, to facilitate Ca2+
exchange between ER and mitochondria following Ca2+ release
from ER stores [1–4,40]. Thus, disruption of the VAPB–PTPIP51
interaction perturbs cellular Ca2+ homoeostasis [5,6]. Since
expression of wild-type or mutant FUS reduced both ER–mito-
chondria and VAPB–PTPIP51 associations, we monitored the
effect of overexpressing FUS on cytosolic and mitochondrial Ca2+
levels after induction of inositol 1,4,5-trisphosphate (IP3) recep-
tor-mediated Ca2+ release from ER stores. For these experiments,
we used HEK293 cells co-transfected with the M3 muscarinic
acetylcholine receptor (M3R) and either control vector or FUS
and triggered physiological IP3 receptor-mediated Ca2+ release
from ER stores by application of the M3R agonist oxotremorine-M.
In line with previous studies on VAPB, PTPIP51 and ER–mitochon-
dria associations, we used HEK293 cells for these experiments
since they do not express endogenous M3R and so provide a useful
model for monitoring cytosolic and mitochondrial Ca2+ levels after
its release from ER specifically in transfected cells [5,6]. Transfec-
tion of both wild-type and mutant FUS all induced significant
increases in cytosolic and decreases in mitochondrial Ca2+ levels
(Fig 4A and B). Such findings are consistent with the observed
FUS-induced decreases in ER–mitochondria and VAPB–PTPIP51
interactions.
Damage to mitochondrial ATP production is a prominent feature
of ALS [9,33,34,44]. Ca2+ is required by mitochondria for generat-
ing ATP via the tricarboxylic acid cycle [45], and so, the reduced
mitochondrial Ca2+ levels seen in FUS-overexpressing cells predict
that FUS impairs mitochondrial ATP production. We therefore moni-
tored the effect of FUS-overexpression on mitochondrial ATP
production using a FRET reporter system that permits ATP quan-
tification in single living transfected cell [46]. Cellular ATP is gener-
ated by a combination of oxidative phosphorylation and glycolysis,
and so, we assayed ATP production in cells treated with potassium
cyanide (KCN), which inhibits cytochrome C oxidase to block oxida-
tive phosphorylation. Monitoring ATP levels in the individually
transfected cells prior to and after KCN treatment thus permits
calculation of the levels of mitochondrial ATP production [46].
These studies revealed that compared to control transfected cells,
both wild-type and mutant FUS reduced mitochondrial ATP produc-
tion (Fig 4C).
FUS activates GSK-3b
To gain insight into the mechanism by which FUS might influ-
ence ER–mitochondria and VAPB–PTPIP51 associations, we first
tested whether FUS bound to either VAPB or PTPIP51. Although
FUS is a predominantly nuclear protein, a proportion is present
in the cytoplasm where it might conceivably bind VAPB and/or
PTPIP51 to disrupt their interaction [26,27]. To do so, we
performed immunoprecipitation assays from FUS+VAPB and
FUS+PTPIP51 transfected cells. However, we detected no binding
of wild-type or ALS-mutant FUS to either protein in these assays
(Fig EV3A and B).
Phosphorylation is a common mechanism for controlling
protein–protein interactions and another ALS/FTD-associated
protein; TDP-43 has been shown to activate GSK-3b to regulate
binding of VAPB to PTPIP51 [6,35]. GSK-3b activity is regulated by
a number of signalling pathways but a major route involves
◀ Figure 2. Expression of wild-type and mutant FUS reduces ER–mitochondria associations and the VAPB–PTPIP51 interaction in NSC34 cells.A FU-induced reductions in ER–mitochondria associations can be detected using SIM. NSC34 cells were transfected with either EGFP control vector, EGFP-FUS, EGFP-
FUSR521C or EGFP-FUSR518K and immunostained for TOM20 and PDI to label mitochondria (Mito) and ER, respectively; FUS was detected via their EGFP tags. Merge
(ZOOM) shows zoomed images of boxed regions, and co-localization shows co-localized pixels. Scale bar = 2 lm. Bar chart shows ER–mitochondria co-localization
(Manders coefficient) normalized to control in the different samples. Data were analysed by one-way ANOVA with Tukey’s post hoc test. A total of 10–14 cells were
analysed per condition from three independent experiments; error bars are s.e.m., **P < 0.01 and ***P < 0.001.
B ER–mitochondria associations and the VAPB–PTPIP51 interaction are disrupted by wild-type and ALS/FTD-mutant FUS. NSC34 cells were transfected with EGFP
control vector (CTRL), EGFP-FUS, EGFP-FUSR521C or EGFP-FUSR518K and proximity ligation assays performed using VAPB and PTPIP51 antibodies. FUS were detected
via their EGFP tags. Scale bar = 10 lm. Bar chart shows relative number of proximity ligation assay signals/cell. Data were analysed by one-way ANOVA and Tukey’s
post hoc test; n = 47–53 cells from five experiments. Error bars are s.e.m.; ***P < 0.001.
C Overexpression of FUS reduces the binding of VAPB to PTPIP51 in transfected cells. Cells were transfected as indicated with either control empty vector (CTRL), HA-
PTPIP51 + CTRL, or HA-PTPIP51 + either EGFP-FUS, EGFP-FUSR521C or EGFP-FUSR518K. PTPIP51 was immunoprecipitated using the HA tag and the amounts of
endogenous bound VAPB detected by immunoblotting. Both inputs and immunoprecipitations (IP) are shown and no immunoprecipitating VAPB signals were
obtained in the absence of HA-PTPIP51. Bar chart shows relative levels of VAPB bound to PTPIP51 in the immunoprecipitations following quantification of signals
from immunoblots. VAPB signals were normalized to immunoprecipitated PTPIP51-HA signals. Data were analysed by one-way ANOVA and Tukey’s post hoc test;
N = 4. Error bars are s.e.m.; ***P < 0.001.
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inhibitory phosphorylation of serine 9 [47]. We therefore analysed
GSK-3b serine 9 phosphorylation in control and FUS-transfected
cells and in control and FUS transgenic mice by immunoblotting.
Remarkably, we found that like TDP-43, overexpression of wild-type
or ALS-mutant FUS activated GSK-3b as evidenced by reduced
serine 9 phosphorylation (Fig 5A and B).
As detailed above, FUS is a predominantly nuclear protein but
a proportion is present in the cytoplasm. The sequences govern-
ing FUS nuclear import reside at its extreme C-terminus [48,49].
To gain insight into whether the FUS-induced increases in GSK-3b
activity and reduced binding of VAPB to PTPIP51 were linked to
the levels of cytosolic FUS, we investigated how these features
were affected by a mutant FUS in which the C-terminal nuclear
localization signal was deleted (FUSDC). Deletion of this nuclear
localization signal has been shown to induce an almost complete
redistribution of FUS to the cytosol [48,49]. Compared to wild-
type FUS, cells transfected with FUSDC displayed increased
GSK-3b activity as evidenced by reduced serine 9 phosphorylation
(Fig 5C). Moreover, this FUSDC-induced increase in GSK-3b activ-
ity was accompanied by a significant decrease in binding of VAPB
to PTPIP51 (Fig 5D). These findings support the notion that the
effects of FUS on the VAPB–PTPIP51 interaction may be linked to
cytosolic FUS.
Inhibition of GSK-3b promotes ER–mitochondria associations and
the VAPB–PTPIP51 interaction
GSK-3b has been shown to regulate binding of VAPB to PTPIP51 in
biochemical assays; inhibition of GSK-3b increases the VAPB–
PTPIP51 interaction [6]. To determine whether GSK-3b also regu-
lates ER–mitochondria associations, we treated NSC34 cells with
two structurally different GSK-3b inhibitors, AR-A014418 and
CT99021, and quantified ER–mitochondria associations by EM. AR-
A014418 and CT99021 are ATP competitive inhibitors so do not
affect GSK-3b serine 9 phosphorylation. Both inhibitors significantly
increased ER–mitochondria associations (Fig 6A). We also quanti-
fied the effects of the GSK-3b inhibitors on ER–mitochondria associ-
ations using VAPB–PTPIP51 proximity ligation assays. Neither
inhibitor altered the size of the cells (% size: vehicle 100  9.26,
AR-A014418 91.16  16.1, CT99021 115.4  20.13; analysed by
one-way ANOVA). However, both inhibitors again induced a signifi-
cant increase in ER–mitochondria associations (Fig 6B). The
A
C
B
Figure 3. Overexpression of FUS reduces ER–mitochondria associations and the VAPB–PTPIP51 interaction in spinal cords of FUS transgenic mice.
A Overexpression of FUS does not affect expression of VAPB, PTPIP51 or mitofusin-2. Immunoblots of spinal cord proteins from three 10-week-old FUS transgenic mice
and three age-matched littermates are shown; FUS was detected via its HA tag. Tubulin was used as a loading control.
B Representative electron micrographs of ER–mitochondria associations in lumbar spinal cord motor neurons of FUS transgenic mice and their non-transgenic
littermates; arrowheads with loops show regions of association. Scale bar = 200 nm. Bar chart shows % of mitochondrial surface closely apposed to ER in the two
samples. Data were analysed by unpaired t-test. N = 67–88 cells and 438–749 mitochondria, error bars are s.e.m.; ***P < 0.001.
C ER–mitochondria associations and the VAPB–PTPIP51 interaction are disrupted in lumbar motor neurons in spinal cords of FUS transgenic mice. Representative
images of proximity ligation signals in 11-week-old FUS and non-transgenic (NTg) littermate mice. Data were analysed by unpaired t-test; N = 40 cells from 3 FUS
and 3 non-transgenic littermates (age 10 weeks). Error bars are s.e.m.; ***P < 0.001.
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VAPB–PTPIP51 proximity ligations assays also complement earlier
biochemical assays involving immunoprecipitation assays, which
likewise demonstrated that GSK-3b inhibitors increase binding of
VAPB to PTPIP51 [6]. Thus and in agreement with previous studies,
GSK-3b is a regulator of both ER–mitochondria associations and the
VAPB–PTPIP51 interaction [6].
A
B
C
Figure 4. Expression of FUS disrupts cellular Ca2+ homoeostasis and mitochondrial ATP production.
A, B FUS disrupts Ca2+ homoeostasis. HEK293 cells were transfected with M3R and either control vector (CTRL), FUS, FUSR521C or FUSR518K as indicated. Release of ER
Ca2+ was induced by treatment of cells with OxoM. Panel (A) shows cytosolic Ca2+ levels with representative Fluo4 fluorescence traces on the left and normalized
peak values on the right. Fluo4 fluorescence shows a transient increase in cytosolic Ca2+ levels upon OxoM treatment but compared to control, wild-type and
mutant FUS all increase peak cytosolic Ca2+ levels. Panel (B) shows mitochondrial Ca2+ levels with representative Rhod2 fluorescence traces on the left and
normalized peak values on the right. Data were analysed by one-way ANOVA and Tukey’s post hoc test. (A) N = 49–52 cells from three experiments; (B) N = 50–52
cells from five experiments, error bars are s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001.
C FUS reduces mitochondrial ATP production. ATP levels were measured in NSC34 cells transfected with the ATP indicator AT1.03 and either control vector (CTRL),
HA-FUS, HA-FUSR521C or HA-FUSR518K. Cells were imaged in time-lapse prior to and after KCN treatment to inhibit oxidative phosphorylation. Representative
traces of YFP/CFP ratios are shown for the different samples; initial YFP/CFP ratios prior to KCN treatment and those after KCN treatment are indicated. The fall in
YFP/CFP ratios correlates with ATP produced by oxidative phosphorylation. Bar chart shows relative ATP levels produced by oxidative phosphorylation (OXPHOS) in
the different samples. Data were analysed by one-way ANOVA and Tukey’s post hoc test. N = 29–54 cells from five experiments, error bars are s.e.m.; *P < 0.05,
***P < 0.001.
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Inhibition of GSK-3b corrects FUS-induced defects in
ER–mitochondria associations and mitochondrial Ca2+ levels
The effects of the GSK-3b inhibitors on ER–mitochondria asso-
ciations and the VAPB–PTPIP51 interaction prompted us to
enquire whether inhibition of GSK-3b might correct defective
ER–mitochondria associations induced by FUS. We therefore
quantified ER–mitochondria associations by EM in FUS-expressing
NSC34 cells treated with either vehicle or the GSK-3b inhibitor
AR-A014418. Treatment with AR-A014418 abrogated the effect of
FUS on ER–mitochondria associations (Fig 7). We also enquired
whether AR-A014418 might correct the FUS-induced damage to
A B
C
D
Figure 5. FUS activates GSK-3b in transfected cells and transgenic mice.
A Cells were transfected with either control vector (CTRL), HA-FUS, HA-FUSR521C or HA FUSR518K and the samples probed on immunoblots for GSK-3b phosphorylated
on serine 9 (GSK-3b-S9), total GSK-3b, FUS (using FUS antibody) and tubulin as a loading control. Phosphorylation of GSK-3b serine 9 is the principal mechanism for
regulating its activity; serine 9 phosphorylation inhibits GSK-3b activity. Bar chart shows relative levels of GSK-3b serine 9 phosphorylation following quantification of
signals from immunoblots and normalization to total GSK-3b signals. Data were analysed by one-way ANOVA and Tukey’s post hoc test. N = 4, error bars are s.e.m.;
*P < 0.05.
B Immunoblots of total and serine 9 phosphorylated GSK-3b in spinal cords from three 10-week-old FUS transgenic mice and their non-transgenic littermates. Samples
were probed for tubulin as a loading control. Bar chart shows relative levels of GSK-3b serine 9 phosphorylation following quantification of signals from immunoblots
and normalization to total GSK-3b signals. Data were analysed by unpaired t-test, error bars are s.e.m.; *P < 0.05.
C Cytosolic FUS activates GSK-3b more potently than wild-type FUS. Cells were transfected with EGFP control, EGFP-FUS or EGFP-FUS lacking its C-terminal nuclear
localization signal (FUSDC). Samples were probed on immunoblots for total GSK-3b, GSK-3b phosphorylated on serine 9, FUS (using EGFP antibody) and tubulin as a
loading control. Bar chart shows relative levels of GSK-3b serine 9 phosphorylation following quantification of signals from immunoblots and normalization to total
GSK-3b signals. Data were analysed by one-way ANOVA and Tukey’s post hoc test. N = 3, error bars are s.e.m.; **P < 0.01, ***P < 0.001.
D Cytosolic FUS reduces the VAPB–PTPIP51 interaction more potently than wild-type FUS. Cells were transfected with PTPIP51-HA, and either EGFP control, EGFP-FUS
or EGFP-FUSDC. PTPIP51 was immunoprecipitated using the HA tag and bound endogenous VAPB detected by immunoblotting. Both inputs and immuno-
precipitations (IP) are shown. FUS was detected using EGFP antibody. Bar chart shows relative levels of VAPB bound to PTPIP51 in the immunoprecipitations
following quantification of signals from immunoblots. VAPB signals were normalized to immunoprecipitated PTPIP51-HA signals. Data were analysed by one-way
ANOVA and Tukey’s post hoc test; N = 3. Error bars are s.e.m.; **P < 0.01, ***P < 0.001.
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AB
Figure 6. Inhibition of GSK-3b increases ER–mitochondria associations and the VAPB–PTPIP51 interaction.
A Representative electron micrographs of ER–mitochondria associations in NSC34 cells treated with either vehicle or GSK-3b inhibitors AR-A014418 (1 lM) or CT99021
(100 nM) for 16 h. Arrowheads with loops show regions of association; scale bar = 200 nm. Bar charts shows % of the mitochondrial surface closely apposed to ER in
the different samples. Data were analysed by one-way ANOVA followed by Tukey’s multiple comparison test. N = 32 cells and 181–210 mitochondria. Error bars are
s.e.m.; *P < 0.05.
B VAPB-PTPIP51 proximity ligation assays of NSC34 cells treated with either vehicle, 1 lM AR-A014418 or 100 nM CT99021 for 16 h. Cells were also stained for nuclei
with DAPI. Bar chart shows relative number of proximity ligation assay signals/cell. Data were analysed by one-way ANOVA and Tukey’s post hoc test; n = 103–173
cells from five experiments. Error bars are s.e.m.; **P < 0.01, ***P < 0.001.
ª 2016 The Authors EMBO reports
Radu Stoica et al ALS/FTD FUS disrupts ER–mitochondria associations EMBO reports
9
Published online: July 14, 2016 
mitochondrial Ca2+ uptake following its release from ER stores.
To do so, we again used HEK293 cells co-transfected with M3R
and either control vector or FUS and triggered physiological IP3
receptor-mediated Ca2+ release from ER stores by application of
oxotremorine-M. In line with the earlier experiments (see Fig 4B),
wild-type and ALS/FTD-mutant FUS all induced a significant
decrease in mitochondrial Ca2+ levels. However, these decreases
were abrogated by pre-treatment with AR-A014418 (Fig 8). Thus,
inhibition of GSK-3b rescues FUS-induced defects to ER–mito-
chondria associations and mitochondrial Ca2+ levels.
Discussion
Although FUS is a predominantly nuclear protein, a proportion is
normally present in the cytoplasm where it has been linked to
Figure 7. Inhibition of GSK-3b rescues defective ER–mitochondria associations induced by FUS.
Representative electron micrographs of ER–mitochondria associations in NSC34 cells transfected with EGFP-FUS, EGFP-FUSR521C or EGFP-FUSR518K and treated with
vehicle or 1 lM AR-A014418 for 16 h. Arrowheads with loops show regions of association; scale bar = 200 nm. Bar charts shows % of the mitochondrial surface closely
apposed to ER in the different samples. Data were analysed by one-way ANOVA followed by Tukey’s multiple comparison test. N = 26–27 cells and 201–236 mitochondria.
Error bars are s.e.m.; *P < 0.05, ***P < 0.001.
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Figure 8. Inhibition of GSK-3b rescues FUS-induced defects in mitochondrial Ca2+ uptake following its release from ER stores.
HEK293 cells were transfected with M3R and either control vector (CTRL), FUS, FUSR521C or FUSR518K and then treated with vehicle (DMSO) or 1 lM AR-A014418 for 16 h as
indicated. Release of ER Ca2+ was induced by treatment of cells with OxoM. Representative Rhod2 fluorescence traces showing mitochondrial Ca2+ are shown along with bar
chart displaying normalized peak values. Data were analysed by one-way ANOVA and Tukey’s post hoc test. N = 30–100 cells from four experiments. Error bars are s.e.m.;
*P < 0.05, ***P < 0.001.
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mRNA translation in ribonucleoprotein complexes, to mRNA trans-
port, mitochondrial function and in neurons, to the regulation of
spine morphology [26,27,50–52]. However, FUS pathogenicity
includes disturbances to mitochondria and to the ER [18,50,53,54];
such phenotypes suggest that FUS may damage the ER–mitochondria
axis. To begin to test this possibility, we monitored the effect
of FUS overexpression on ER–mitochondria associations. We
show here that wild-type and familial ALS-mutant FUS decrease
ER–mitochondria associations in both NSC34 motor neuron cells and
transgenic mice.
Our findings that wild-type as well as mutant FUS decrease
ER–mitochondria associations are consistent with the phenotypes
observed in FUS transgenic mice where both wild-type and mutant
FUS induce disease [18–23]. Indeed, in one study that compared
directly transgenic mice expressing wild-type or ALS-mutant FUS-
R521G at levels similar to endogenous mouse FUS, the mice
expressing wild-type FUS displayed lower survival rates than the
mutants [23]. The reasons behind this effect are not properly under-
stood but there is evidence that mutations in the 30 untranslated
region (UTR) of FUS cause both familial and sporadic ALS by
increasing wild-type FUS protein expression [55]. Recently, the
effects of the 30 UTR mutations have been shown to involve disrup-
tion to a FUS–microRNA regulatory circuit [56]. Thus, both clinical
genetic evidence and experimental evidence involving multiple
transgenic mouse studies demonstrate that overexpression of wild-
type FUS induces disease. Interestingly, a similar feature may exist
for TDP-43 in ALS/FTD since the expression of the wild-type protein
likewise induces aggressive disease in mice and a 30-UTR TDP-43
variant linked to ALS also increases expression [57,58]. Like FUS,
both wild-type and mutant TDP-43 disrupt ER–mitochondria associ-
ations to similar extents [6]. Indeed, the FUS and TDP-43 results in
ALS/FTD complement findings in familial Alzheimer’s and Parkin-
son’s diseases where mutation and overexpression of wild-type
amyloid precursor protein and a-synuclein involving increased gene
dosage cause disease [59–63].
ER–mitochondria associations control Ca2+ exchange between
the two organelles, and this can impact upon the ability of mito-
chondria to generate ATP [1,45]. This is because the ER represents a
primary source of mitochondrial Ca2+ and several mitochondrial
dehydrogenases in the TCA cycle are Ca2+ regulated [45]. Our find-
ings that FUS decreases mitochondrial Ca2+ levels following IP3
receptor-mediated Ca2+ release from ER stores and that this trans-
lates into reduced ATP levels is thus consistent with the loosening
of ER–mitochondria contacts seen in FUS-expressing cells.
Damage to mitochondria is a major feature of ALS and a
number of mutant proteins linked to familial ALS perturb mito-
chondrial function and/or biogenesis [9]. These include mutant
Cu/Zn superoxide dismutase-1 (SOD1), TDP-43, optineurin, TANK-
binding kinase-1 and valosin-containing protein (VCP) [28–33].
More recently, FUS too has been linked to mitochondrial damage
[18,50,64,65]. A primary function of mitochondria is the genera-
tion of ATP, and reduced ATP levels are increasingly linked to the
neurodegenerative process in ALS/FTD. For example, mutant
SOD1, VCP and Sigma-R1 mutations all lower mitochondrial ATP
production [33,44,66]. Indeed, elegant recent studies have demon-
strated that relatively small reductions in ATP levels (similar to
those we detect in the FUS-expressing cells) can induce
many salient features of ALS [34]. Thus, the reductions in
ER–mitochondria interactions and associated disruptions to mito-
chondrial Ca2+ levels and ATP production are likely to contribute
to FUS pathogenesis.
VAPB and PTPIP51 represent tethering molecules, which inter-
act to mediate ER–mitochondria associations [5,6], and we
showed that the FUS-induced reductions to ER–mitochondria
contacts involved reduced binding of VAPB to PTPIP51. Such find-
ings support the notion that FUS targets the VAPB–PTPIP51
complex for damage. FUS is involved in transcription and mRNA
metabolism, but we detected no changes in the levels of either
VAPB or PTPIP51 in cells overexpressing wild-type or mutant
FUS, nor in FUS siRNA knockdown cells. Thus, the FUS-induced
changes in binding of VAPB to PTPIP51 are not the result of alter-
ations to their expression.
As a further possibility, we tested whether FUS bound to either
VAPB or PTPIP51; such binding might sterically inhibit the VAPB–
PTPIP51 interaction. We detected no binding of wild-type or mutant
FUS to either VAPB or PTPIP51 in immunoprecipitation assays,
which suggest that FUS is not a major binding partner for VAPB or
PTPIP51. However, we cannot eliminate the possibility that a
proportion of FUS, beyond the sensitivity of our assays interacts
with either VAPB or PTPIP51 and that this might contribute to
changes in the VAPB–PTPIP51 interaction.
Finally, we monitored whether FUS might activate GSK-3b since
GSK-3b has been shown previously to regulate binding of VAPB to
PTPIP51; activation of GSK-3b decreases the VAPB–PTPIP51 inter-
action [6]. FUS activated GSK-3b in both transfected cells and in
the FUS transgenic mice. Moreover, inhibition of GSK-3b increased
ER–mitochondria associations and rescued the FUS-induced disrup-
tions to ER–mitochondria associations and mitochondrial Ca2+
levels. Thus, GSK-3b is a regulator of VAPB–PTPIP51 interactions
and ER–mitochondria associations, and the effect of FUS on ER–
mitochondria associations is linked to activation of GSK-3b. At this
stage, the precise mechanism by which GSK-3b influences binding
of VAPB to PTPIP51 is not clear; it may be via direct phosphoryla-
tion of VAPB and/or PTPIP51 to inhibit their binding, or by signal-
ling to downstream effectors that somehow influence VAPB/
PTPIP51 phosphorylation and/or binding. Future studies to identify
and functionally characterize any VAPB and PTPIP51 phosphoryla-
tion sites would assist in discriminating between these possibilities.
Recently, two other familial ALS/FTD-linked proteins, TDP-43
and the Sigma-1 receptor have been shown to disrupt ER–
mitochondria associations [6,11]. The Sigma-1 receptor is a chap-
erone that localizes to the regions of ER apposed to mitochondria
(MAM) [3,11], but the mechanisms linking it to loosening of
ER–mitochondria contacts and disease are not clear. However, the
TDP-43-induced disruption to ER–mitochondria contacts is associ-
ated with reduced binding of VAPB to PTPIP51 that involves acti-
vation of GSK-3b [6]. Thus, three different ALS/FTD insults
perturb ER–mitochondria associations and for FUS and TDP-43 at
least, the mechanisms involve activation of GSK-3b.
One difficulty in deciphering ALS/FTD pathogenicity is that it
involves damage to a large number of physiological processes.
These include disruptions to Ca2+ signalling, lipid and energy meta-
bolism, mitochondria, the ER involving activation of the unfolded
protein response, axonal transport and autophagy [9,10]. However,
all of these cellular functions are regulated by ER–mitochondria
associations [1–3,10]. Thus, damage to the ER–mitochondria axis
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may provide an explanation for many of the seemingly disparate
pathological features of ALS/FTD.
Recently, damage to ER–mitochondria associations have also
been described in both Alzheimer’s and Parkinson’s diseases
[43,67–73]. Perturbation of the ER–mitochondria axis may therefore
be a general feature of all of the major human neurodegenerative
diseases. As such, the results describe here and in these other
reports highlight the ER–mitochondria axis as a new therapeutic
target for neurodegenerative diseases.
Materials and Methods
Plasmids and siRNAs
Mammalian expression vectors for HA-PTPIP51, HA-FUS, HA-
FUSR521C and myc-VAPB all in pCIneo, EGFP-FUS, EGFP-FUSDC
(FUSK510X), M3R, ATeam AT1.03 and control pCIneo vector
expressing E. coli chloramphenicol acetyltransferase (CAT) have
been described previously [5,6,46,48,74]. FUSR518K was created
using a QuikChange XL mutagenesis kit (Stratagene). Mutagenic
primers were 50-CCAGGGGTGAGCACAAACAGGATCGCAGGGAG-30
and 50-CTCCCTGCGATCCTGTTTGTGCTCACCCCTGG-30. Control
and FUS siRNAs were from Dharmacon; FUS siRNA sequences were
UCGACUGGUUUGAUGGUAA and GACUAUACCCAACAAGCAA and
were applied together.
Antibodies and inhibitors
Rat and rabbit antibodies to VAPB and PTPIP51 have been
described previously and were generated by immunization with
GST-VAPB(1–220) and GST-PTPIP51(36–470) [5]. Rabbit PTPIP51
antibody (FAM82A2) was from Atlas Antibodies. Rabbit anti-
haemagglutinin (HA), mouse anti-a-tubulin (DM1A) and rabbit
anti-mitofusin-2 were from Sigma. Mouse anti-myc (9B11) and
rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were from Cell Signaling. Rabbit anti-FUS (NB100-565) was from
Novus Biologicals. Rabbit anti-TOM20 was from Santa Cruz
Biotechnology and mouse anti-PDI (RL77) was from Affinity Biore-
agents. Antibodies to total and ser9 phosphorylated (inactive)
GSK-3b were from BD Transduction Labs (mouse 610201) and Cell
Signalling (rabbit 9336), respectively. Rabbit anti-GFP (Ab290) was
from Abcam. GSK-3b inhibitors AR-A014418 and CT99021 were
from Abcam and Cayman, respectively, and made up as 1 mM or
100 lM stocks in DMSO; KCN was from Sigma and made up as a
1 M stock in water.
Cell culture and transfection
NSC34 cells were provided by Professor Dame Pamela Shaw
(University of Sheffield, UK), and HEK293 cells were obtained from
the ATCC. Cells were grown in Dulbecco’s modified Eagle’s medium
containing 10% foetal bovine serum supplemented with 2 mM
glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin. NSC34
cells transfected with plasmids or siRNAs using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions; HEK293
cells were transfected with Fugene 6 (Roche) according to the manu-
facturers’ instructions. Except where stated, plasmid-transfected
cells were analysed 36 h post-transfection; siRNA-treated cells were
analysed 3 days post-treatment. For fluorescence-activated flow
cytometry cell sorting, NSC34 were trypsinized, resuspended in
phosphate-buffered saline (PBS) and then sorted for EGFP expres-
sion using a BD FACSAria cell sorter, re-plated and cultured for a
further 16 h prior to processing.
Electron microscopy
For EM, NSC34 cells were fixed with 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer (pH 7.2) for 3 h and then harvested by
scraping gently with a plastic scraper. The cells were pelleted by
centrifugation at 800 g for 10 min, washed in buffer and post-fixed
for 1 h in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer.
The cells were then stained for 1 h with 1% uranyl acetate in water
before dehydration and embedding in TAAB resin. Mice were
perfusion fixed in 2.5% glutaraldehyde/2% paraformaldehyde in
PBS and spinal cords dissected and immersed in 2.5% glutaralde-
hyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer
(pH 7.2) for 16 h. Samples were then post-fixed in 1% osmium
tetroxide, dehydrated in alcohol and propylene oxide and finally
embedded in Epon 81226. Sections were counterstained with lead
citrate and uranyl acetate and samples viewed on a Tecnai 12 elec-
tron microscope at 6,800 or 9,300 magnification. Digital images
were acquired and the circumference of each mitochondria and the
proportions of the mitochondrial surface (circumference) closely
associated (< 30 nm) with ER were calculated. Cells were
randomly selected for analyses without prior knowledge of trans-
fected plasmid, siRNA or mouse genotype. All clearly identified
mitochondria in the samples were scored. Image analyses were
performed using ImageJ and statistical analyses determined using
GraphPad Prism.
Super resolution structured illumination microscopy
NSC-34 cells plated on glass coverslips were fixed with 3%
paraformaldehyde and 0.1% glutaraldehyde in phosphate-buffered
saline (PBS) for 10 min at 20°C. After washing with PBS, samples
were quenched by incubation with 50 mM NaBH4 in PBS for 7 min,
washed in PBS and then permeabilized for 30 min in PBS contain-
ing 0.2% Triton X-100 and 3% bovine serum albumin (BSA).
Following blocking with 3% BSA in PBS, samples were incubated
with primary antibodies diluted in blocking solution, washed with
PBS and incubated with goat anti-rabbit or anti-mouse secondary
Igs conjugated to AlexaFluor 546 or AlexaFluor 633 (1:1,000) (Invit-
rogen). Following final washings in PBS, the samples were mounted
in Mowiol-DABCO mounting medium containing 10% (w/v)
Mowiol 4-88 (Calbiochem), 25% (w/v) glycerol and 2.5% (w/v)
DABCO (1,4-diazobicyclo[2.2.2]octane) in 100 mM Tris–HCl pH
8.5. Samples were analysed on a Nikon Eclipse Ti-E inverted micro-
scope equipped with a Nikon N-SIM Super Resolution System.
Confocal images were captured using a CFI Plan Apo IR SR 60X
water immersion objective and then reconstructed using Nikon
Imaging Software Elements AR with N-SIM module. ER–mitochon-
dria interactions were quantified by Mander’s coefficient using
ImageJ software. Co-localized signals were displayed using the
ImageJ 1.44p RG2B co-localization plug-in to determine co-localized
pixels.
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Immunoprecipitations, SDS–PAGE and immunoblotting
Cells were harvested for SDS–PAGE and immunoblotting by scrap-
ing into SDS–PAGE sample buffer containing 2% SDS, 100 mM
dithiothreitol, 10% glycerol, 0.1% bromophenol blue and protease
inhibitors (Complete Roche) in 50 mM Tris–HCl pH 6.8 and heating
to 100°C for 5 min. Transgenic mouse samples were homogenized
in 50 mM Tris–citrate pH 7.4, 150 mM NaCl, 1% Triton X-100,
5 mM ethylene glycol tetraacetic acid, 5 mM EDTA and protease
inhibitors (Complete, Roche) and then prepared for SDS–PAGE by
addition of SDS–PAGE sample buffer and heating to 100°C for
5 min.
For immunoprecipitation assays, transfected cells were lysed in
ice-cold immunoprecipitation buffer comprising 50 mM Tris–citrate
pH 7.4, 150 mM NaCl, 1% Triton X-100, 5 mM ethylene glycol tetra-
acetic acid, 5 mM EDTA and protease inhibitors (Complete, Roche).
The samples were then centrifuged at 13,000 g for 20 min, and the
supernatants were transferred to fresh tubes and precleared by incu-
bation with Protein-G-Sepharose beads (prepared as a 50% slurry in
PBS containing 0.1% Triton X-100). Following centrifugation at
2,000 g for 30 s to settle the beads, supernatants were transferred to
fresh tubes and protein concentrations were determined using a
Bio-Rad protein assay kit. The protein concentrations were adjusted
to 1 mg/ml, and 500 lg of protein was incubated with appropriate
primary antibodies on a rotary shaker for 16 h at 4°C. Antibodies
were then captured by addition of 30 ll Protein-G-sepharose beads
(50% slurry in PBS/0.1% Triton X-100). Following washing in PBS/
0.1% Triton X-100, bound proteins were prepared for SDS–PAGE by
addition of 50 ll SDS–PAGE sample buffer and heating to 100°C.
Samples were separated on 10% (w/v) acrylamide gels and
transferred to Protran nitrocellulose membranes (Schleicher &
Schuell) using a Mini-PROTEAN 3 gel electrophoresis system and
Transblot system (Bio-Rad). Following blocking in 5% (w/v)
dried milk/0.1% w/v Tween-20 in TBS, the immunoblots were
probed with primary antibodies diluted in blocking solution and
after washing in blocking solution, incubated with horseradish
peroxidase-conjugated goat anti-mouse, anti-rabbit or anti-rat Igs
(GE Healthcare). Immunoblots were developed using an enhanced
chemiluminescence system (GE Healthcare). Signals on immuno-
blots were quantified using ImageJ after scanning with an Epson
Precision V700 Photo scanner essentially as described by us in
previous studies [6]. To ensure the signals obtained were within
the linear range, the mean background-corrected optical density
(OD) of each signal was interpolated for an OD calibration curve
created using a calibrated OD step tablet (Kodak). Only film
exposures that gave OD signals within the linear range of the
OD calibration curve were used for statistical analyses. Some
signals were also quantified on a Bio-Rad ChemiDoc MP Imaging
System.
Proximity ligation assays
Proximity ligation assays to quantify VAPB–PTPIP51 interactions
were performed essentially as described previously using Duolink
reagents (Olink Bioscience) [5]. For cultured cells, cells were fixed
in 4% paraformaldehyde in PBS and probed with rabbit anti-VAPB
and rat anti-PTPIP51 antibodies. Signals were developed using the
Duolink In Situ Orange kit; control samples were counterstained
with 40,6-diamidino-2-phenylindole (DAPI) to show nuclei. For
mouse spinal cords, paraformaldehyde perfusion fixed spinal cords
were post-fixed in 4% paraformaldehyde containing 15% sucrose in
PBS for 5 h, cryoprotected in 30% sucrose in PBS for 24 h and
30-lm sections were prepared using a cryostat. Samples were
probed with rabbit anti-VAPB and rat anti-PTPIP51 antibodies.
Signals were developed using the Duolink In Situ Brightfield kit and
sections counterstained with Mayer’s haematoxylin. NSC34 cells
were imaged using a DM5000 fluorescence microscope (Leica
Microsystems) equipped with a 40×/0.75NA HCX-PL-FLUOTAR
lens; spinal cord sections were imaged using an Axioplan micro-
scope (Zeiss) with Axiovision software. Cell sizes were determined
using ImageJ and proximity ligation assay signals quantified using
the particle analysis function of ImageJ. Statistical analyses were
performed using GraphPad Prism.
Ca2+ measurements
Cytosolic and mitochondrial Ca2+ levels were measured following
IP3 receptor-mediated Ca2+ release from ER stores as previously
described [5]. Briefly, HEK293 cells co-transfected with M3R and
either empty vector or FUS was loaded with 2 lM Fluo4-AM or
Rhod2-AM dye (Invitrogen) in external solution (145 mM NaCl,
2 mM KCl, 5 mM NaHCO3, 1 mM MgCl2, 2.5 mM CaCl2, 10 mM
glucose, 10 mM Na-HEPES pH 7.25) containing 0.02% Pluronic-
F27 (Invitrogen) for 15 min at 37°C, followed by washing in
external solution for 15 min. Fluo4 and Rhod2 fluorescences were
timelapse recorded (1 s intervals) with MetaMorph (Molecular
Dynamics) on an Axiovert S100 microscope (Zeiss) equipped with
appropriate filter sets (Chroma Technology), a 40×/1.3NA Plan-
Neofluar objective (Zeiss) and a Photometrics Cascade-II 512B
EMCCD. The cells were kept under constant perfusion with exter-
nal solution (0.5 ml/min). IP3 receptor-mediated Ca2+ release from
ER stores was triggered by application of 100 lM oxotremorine-M
(Tocris) for 2 min. Ca2+ levels were calculated as relative Fluo4 or
Rhod2 fluorescence compared to baseline fluorescence at the start
of the measurement.
For monitoring the effects of GSK-3b inhibition on mitochondrial
Ca2+ levels, HEK293 cells were co-transfected with M3R and either
control vector, FUS, FUS-R521C or FUSR518K for 24 h and then
treated with AR-A014418 for a further 16 h. Ca2+ measurements
were performed essentially as described above except using a Nikon
Ti-E microscope using a CFI Plan Apo VC 20× objective and Nikon
Andor Neo sCMOD high-resolution camera.
ATP measurements
ATP levels in control and FUS-transfected cells were determined
using a FRET-based plasmid reporter (Adenosine 50-Triphosphate
indicator based on Epsilon subunit for Analytical Measurements;
ATeam reporter) [46]. To do so, NSC34 cells were co-transfected
with AT1.03 cytosolic ATeam reporter and either control vector,
FUS, FUSR521C or FUSR518K. Cells were imaged in Hanks’
balanced salt solution (HBSS) without phenol red at 37°C by time-
lapse microscopy (12 s intervals) on a Zeiss Axiovert S100 micro-
scope equipped with a 40×/1.3NA Plan-Neofluar objective and a
Photometrics Cascade-II 512B EMCCD driven by MetaMorph
(Molecular Dynamics). FRET filtersets (ECFP excitation filter ET
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430/24×; ECFP emission filter 470/24 m; EYFP emission filter
ET545/40 m) were from Chroma Technology. KCN 1 mM in HBSS
was applied using a peristaltic pump (0.5 ml/min). YFP/CFP ratios
prior to and after KCN treatment were measured as described and
used to calculate relative ATP levels in the different samples, which
were displayed as bar charts [46].
Expanded View for this article is available online.
Acknowledgements
This work was supported by grants from the UK Medical Research Council,
Alzheimer’s Research UK, The Wellcome Trust, the Motor Neurone Disease
Association, Parkinson’s UK and the Rosetrees Trust. We also thank staff in the
King’s College Nikon Imaging Centre for microscopy assistance.
Author contributions
CCJM, RS, SP, PG-S and KJDV designed the experiments. RS, SP, PG-S,
DHWL and GV-B performed the experiments. JCM, EHG, RMS and CES
provided reagents. CCJM, RS, SP, PG-S, DHWL, WN, DPH and KJDV wrote
the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
References
1. Rowland AA, Voeltz GK (2012) Endoplasmic reticulum-mitochondria
contacts: function of the junction. Nat Rev Mol Cell Biol 13: 607 – 625
2. Kornmann B (2013) The molecular hug between the ER and the mito-
chondria. Curr Opin Cell Biol 25: 443 – 448
3. van Vliet A, Verfaillie T, Agostinis P (2014) New functions of mitochon-
dria associated membranes in cellular signalling. Biochim Biophys Acta
1843: 2253 – 2262
4. Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF, Balla T,
Mannella CA, Hajnoczky G (2006) Structural and functional features and
significance of the physical linkage between ER and mitochondria. J Cell
Biol 174: 915 – 921
5. De Vos KJ, Morotz GM, Stoica R, Tudor EL, Lau KF, Ackerley S, Warley A,
Shaw CE, Miller CCJ (2012) VAPB interacts with the mitochondrial protein
PTPIP51 to regulate calcium homeostasis. Hum Mol Genet 21: 1299 – 1311
6. Stoica R, De Vos KJ, Paillusson S, Mueller S, Sancho RM, Lau KF, Vizcay-
Barrena G, Lin WL, Xu YF, Lewis J et al (2014) ER-mitochondria associa-
tions are regulated by the VAPB-PTPIP51 interaction and are disrupted
by ALS/FTD-associated TDP-43. Nat Commun 5: 3996
7. Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms
in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79:
416 – 438
8. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in under-
standing the molecular basis of frontotemporal dementia. Nat Rev
Neurol 8: 423 – 434
9. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ (2011) Molecular
pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat
Rev Neurol 7: 616 – 630
10. Paillusson S, Stoica R, Gomez-Suaga P, Lau DH, Mueller S, Miller T,
Miller CC (2016) There’s something wrong with my MAM; the ER-mito-
chondria axis and neurodegenerative diseases. Trends Neurosci 39:
146 – 157
11. Bernard-Marissal N, Medard JJ, Azzedine H, Chrast R (2015) Dysfunction
in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1
loss of function mediated motor neuron degeneration. Brain 138:
875 – 890
12. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S,
Durnall JC, Williams KL, Buratti E et al (2008) TDP-43 mutations in
familial and sporadic amyotrophic lateral sclerosis. Science 319:
1668 – 1672
13. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou
TT, Bruce J, Schuck T, Grossman M, Clark CM et al (2006) Ubiquitinated
TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Science 314: 130 – 133
14. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D,
Tsuchiya K, Yoshida M, Hashizume Y et al (2006) TDP-43 is a compo-
nent of ubiquitin-positive tau-negative inclusions in frontotemporal
lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys
Res Commun 351: 602 – 611
15. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlstrom H,
Sobow T, Tchorzewska J, Maruszak A, Barcikowska M et al (2010) Sigma
nonopioid intracellular receptor 1 mutations cause frontotemporal lobar
degeneration-motor neuron disease. Ann Neurol 68: 639 – 649
16. Al-Saif A, Al-Mohanna F, Bohlega S (2011) A mutation in sigma-1 recep-
tor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 70:
913 – 919
17. Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in
amyotrophic lateral sclerosis and frontotemporal dementia. Lancet
Neurol 9: 995 – 1007
18. Huang C, Tong J, Bi F, Wu Q, Huang B, Zhou H, Xia XG (2012) Entorhinal
cortical neurons are the primary targets of FUS mislocalization and
ubiquitin aggregation in FUS transgenic rats. Hum Mol Genet 21:
4602 – 4614
19. Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B,
Tudor EL, Smith BN, Klasen C, Miller CC et al (2012) Overexpression of
human wild-type FUS causes progressive motor neuron degeneration in
an age- and dose-dependent fashion. Acta Neuropathol 125: 273 – 288
20. Qiu H, Lee S, Shang Y, Wang WY, Au KF, Kamiya S, Barmada SJ, Fink-
beiner S, Lui H, Carlton CE et al (2014) ALS-associated mutation FUS-
R521C causes DNA damage and RNA splicing defects. J Clin Invest 124:
981 – 999
21. Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H,
Ustyugov AA, Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER
et al (2013) Fused in Sarcoma (FUS) protein lacking nuclear localization
signal (NLS) and major RNA binding motifs triggers proteinopathy and
severe motor phenotype in transgenic mice. J Biol Chem 288:
25266 – 25274
22. Verbeeck C, Deng Q, Dejesus-Hernandez M, Taylor G, Ceballos-Diaz C,
Kocerha J, Golde T, Das P, Rademakers R, Dickson DW et al (2012)
Expression of Fused in sarcoma mutations in mice recapitulates the
neuropathology of FUS proteinopathies and provides insight into disease
pathogenesis. Mol Neurodegener 7: 53
23. Sephton CF, Tang AA, Kulkarni A, West J, Brooks M, Stubblefield JJ, Liu Y,
Zhang MQ, Green CB, Huber KM et al (2014) Activity-dependent FUS
dysregulation disrupts synaptic homeostasis. Proc Natl Acad Sci USA 111:
E4769 – E4778
24. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J,
Hu X, Smith B, Ruddy D, Wright P et al (2009) Mutations in FUS, an
RNA processing protein, cause familial amyotrophic lateral sclerosis type
6. Science 323: 1208 – 1211
ª 2016 The Authors EMBO reports
Radu Stoica et al ALS/FTD FUS disrupts ER–mitochondria associations EMBO reports
15
Published online: July 14, 2016 
25. Kwiatkowski TJ Jr, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR,
Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T et al (2009) Mutations
in the FUS/TLS gene on chromosome 16 cause familial amyotrophic
lateral sclerosis. Science 323: 1205 – 1208
26. Dormann D, Haass C (2013) Fused in Sarcoma (FUS): an oncogene goes
awry in neurodegeneration. Mol Cell Neurosci 56: 475 – 486
27. Deng H, Gao K, Jankovic J (2014) The role of FUS gene variants in
neurodegenerative diseases. Nat Rev Neurol 10: 337 – 348
28. Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz
V, Cleveland DW (2010) Misfolded mutant SOD1 directly inhibits VDAC1
conductance in a mouse model of inherited ALS. Neuron 67: 575 – 587
29. Shan X, Chiang PM, Price DL, Wong PC (2010) Altered distributions of
Gemini of coiled bodies and mitochondria in motor neurons of TDP-43
transgenic mice. Proc Natl Acad Sci USA 107: 16325 – 16330
30. Xu YF, Gendron TF, Zhang YJ, Lin WL, D’Alton S, Sheng H, Casey MC,
Tong J, Knight J, Yu X et al (2010) Wild-type human TDP-43 expression
causes TDP-43 phosphorylation, mitochondrial aggregation, motor defi-
cits, and early mortality in transgenic mice. J Neurosci 30:
10851 – 10859
31. Wong YC, Holzbaur EL (2014) Optineurin is an autophagy receptor for
damaged mitochondria in parkin-mediated mitophagy that is disrupted
by an ALS-linked mutation. Proc Natl Acad Sci USA 111: E4439 – E4448
32. Heo JM, Ordureau A, Paulo JA, Rinehart J, Harper JW (2015) The PINK1-
PARKIN mitochondrial ubiquitylation pathway drives a program of
OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy.
Mol Cell 60: 7 – 20
33. Bartolome F, Wu HC, Burchell VS, Preza E, Wray S, Mahoney CJ, Fox NC,
Calvo A, Canosa A, Moglia C et al (2013) Pathogenic VCP mutations induce
mitochondrial incoupling and reduced ATP levels. Neuron 78: 57 – 64
34. Le Masson G, Przedborski S, Abbott LF (2014) A computational model of
motor neuron degeneration. Neuron 83: 975 – 988
35. Ambegaokar SS, Jackson GR (2011) Functional genomic screen and
network analysis reveal novel modifiers of tauopathy dissociated from
tau phosphorylation. Hum Mol Genet 20: 4947 – 4977
36. Moujalled D, James JL, Parker SJ, Lidgerwood GE, Duncan C, Meyerowitz
J, Nonaka T, Hasegawa M, Kanninen KM, Grubman A et al (2013) Kinase
inhibitor screening identifies cyclin-dependent kinases and glycogen
synthase kinase 3 as potential modulators of TDP-43 cytosolic accumu-
lation during cell stress. PLoS ONE 8: e67433
37. Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, Ngo
HD, Rosowski KA, Schein PA, Ackeifi CA et al (2013) A small molecule
screen in stem-cell-derived motor neurons identifies a kinase inhibitor
as a candidate therapeutic for ALS. Cell Stem Cell 12: 713 – 726
38. Zhou Y, Liu S, Liu G, Ozturk A, Hicks GG (2013) ALS-associated FUS
mutations result in compromised FUS alternative splicing and autoregu-
lation. PLoS Genet 9: e1003895
39. Cosson P, Marchetti A, Ravazzola M, Orci L (2012) Mitofusin-2 indepen-
dent juxtaposition of endoplasmic reticulum and mitochondria: an
ultrastructural study. PLoS ONE 7: e46293
40. de Brito OM, Scorrano L (2008) Mitofusin 2 tethers endoplasmic reticu-
lum to mitochondria. Nature 456: 605 – 610
41. Hirano Y, Matsuda A, Hiraoka Y (2015) Recent advancements in struc-
tured-illumination microscopy toward live-cell imaging. Microscopy 64:
237 – 249
42. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ,
Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG et al (2006) Direct
observation of individual endogenous protein complexes in situ by prox-
imity ligation. Nat Methods 3: 995 – 1000
43. Hedskog L, Pinho CM, Filadi R, Ronnback A, Hertwig L, Wiehager B,
Larssen P, Gellhaar S, Sandebring A, Westerlund M et al (2013) Modula-
tion of the endoplasmic reticulum-mitochondria interface in Alzheimer’s
disease and related models. Proc Natl Acad Sci USA 110: 7916 – 7921
44. Coussee E, De Smet P, Bogaert E, Elens I, Van Damme P, Willems P,
Koopman W, Van Den Bosch L, Callewaert G (2011) G37R SOD1 mutant
alters mitochondrial complex I activity, Ca(2+) uptake and ATP produc-
tion. Cell Calcium 49: 217 – 225
45. Griffiths EJ, Rutter GA (2009) Mitochondrial calcium as a key regulator
of mitochondrial ATP production in mammalian cells. Biochim Biophys
Acta 1787: 1324 – 1333
46. Imamura H, Nhat KP, Togawa H, Saito K, Iino R, Kato-Yamada Y, Nagai
T, Noji H (2009) Visualization of ATP levels inside single living cells with
fluorescence resonance energy transfer-based genetically encoded indi-
cators. Proc Natl Acad Sci USA 106: 15651 – 15656
47. Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: functional insights
from cell biology and animal models. Front Mol Neurosci 4: 40
48. Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C,
Urwin H, Manser C, Miller CC, Hortobagyi T et al (2013) ALS mutant
FUS disrupts nuclear localisation and sequesters wild-type FUS within
cytoplasmic stress granules. Hum Mol Genet 22: 2676 – 2688
49. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A,
Than ME, Mackenzie IR, Capell A, Schmid B et al (2010) ALS-associated
fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear
import. EMBO J 18: 2841 – 2857
50. Deng J, Yang M, Chen Y, Chen X, Liu J, Sun S, Cheng H, Li Y, Bigio EH,
Mesulam M et al (2015) FUS interacts with HSP60 to promote mito-
chondrial damage. PLoS Genet 11: e1005357
51. Fujii R, Okabe S, Urushido T, Inoue K, Yoshimura A, Tachibana T, Nishi-
kawa T, Hicks GG, Takumi T (2005) The RNA binding protein TLS is
translocated to dendritic spines by mGluR5 activation and regulates
spine morphology. Curr Biol 15: 587 – 593
52. Yasuda K, Zhang H, Loiselle D, Haystead T, Macara IG, Mili S (2013) The
RNA-binding protein Fus directs translation of localized mRNAs in APC-
RNP granules. J Cell Biol 203: 737 – 746
53. Soo KY, Halloran M, Sundaramoorthy V, Parakh S, Toth RP, Southam
KA, McLean CA, Lock P, King A, Farg MA et al (2015) Rab1-dependent
ER-Golgi transport dysfunction is a common pathogenic mechanism
in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol 130:
679 – 697
54. Farg MA, Soo KY, Walker AK, Pham H, Orian J, Horne MK, Warraich ST,
Williams KL, Blair IP, Atkin JD (2012) Mutant FUS induces endoplasmic
reticulum stress in amyotrophic lateral sclerosis and interacts with
protein disulfide-isomerase. Neurobiol Aging 33: 2855 – 2868
55. Sabatelli M, Moncada A, Conte A, Lattante S, Marangi G, Luigetti M,
Lucchini M, Mirabella M, Romano A, Del Grande A et al (2013) Mutations
in the 30 untranslated region of FUS causing FUS overexpression are
associated with amyotrophic lateral sclerosis. Hum Mol Genet 22:
4748 – 4755
56. Dini Modigliani S, Morlando M, Errichelli L, Sabatelli M, Bozzoni I (2014)
An ALS-associated mutation in the FUS 30-UTR disrupts a microRNA-FUS
regulatory circuitry. Nat Commun 5: 4335
57. Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM, Wong PC (2012)
Rodent models of TDP-43: recent advances. Brain Res 1462: 26 – 39
58. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M,
Rademakers R, Chakraverty S, Cruchaga C, Morris JC et al (2009) TARDBP
30-UTR variant in autopsy-confirmed frontotemporal lobar degeneration
with TDP-43 proteinopathy. Acta Neuropathol 118: 633 – 645
EMBO reports ª 2016 The Authors
EMBO reports ALS/FTD FUS disrupts ER–mitochondria associations Radu Stoica et al
16
Published online: July 14, 2016 
59. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J,
Hulihan M, Peuralinna T, Dutra A, Nussbaum R et al (2003) Alpha-Synu-
clein locus triplication causes Parkinson’s disease. Science 302: 841
60. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y,
Durr A, Brice A (2004) Causal relation between alpha-synuclein gene
duplication and familial Parkinson’s disease. Lancet 364: 1169 – 1171
61. Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerriere A, Vital A,
Dumanchin C, Feuillette S, Brice A, Vercelletto M et al. (2006) APP locus
duplication causes autosomal dominant early-onset Alzheimer disease
with cerebral amyloid angiopathy. Nat Genet 38: 24 – 26
62. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J,
Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C (2006) APP
duplication is sufficient to cause early onset Alzheimer’s dementia with
cerebral amyloid angiopathy. Brain 129: 2977 – 2983
63. Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la Four-
niere F, Thomas-Anterion C, Verny C, Letournel F, Pasquier F, Vital A
et al (2006) Phenotype associated with APP duplication in five families.
Brain 129: 2966 – 2976
64. Tradewell ML, Yu Z, Tibshirani M, Boulanger MC, Durham HD, Richard S
(2012) Arginine methylation by PRMT1 regulates nuclear-cytoplasmic
localization and toxicity of FUS/TLS harbouring ALS-linked mutations.
Hum Mol Genet 21: 136 – 149
65. Huang EJ, Zhang J, Geser F, Trojanowski JQ, Strober JB, Dickson DW,
Brown RH Jr, Shapiro BE, Lomen-Hoerth C (2010) Extensive FUS-immu-
noreactive pathology in juvenile amyotrophic lateral sclerosis with baso-
philic inclusions. Brain Pathol 20: 1069 – 1076
66. Tagashira H, Shinoda Y, Shioda N, Fukunaga K (2014) Methyl pyruvate
rescues mitochondrial damage caused by SIGMAR1 mutation related to
amyotrophic lateral sclerosis. Biochim Biophys Acta 1840: 3320 – 3334
67. Sepulveda-Falla D, Barrera-Ocampo A, Hagel C, Korwitz A, Vinueza-Veloz
MF, Zhou K, Schonewille M, Zhou H, Velazquez-Perez L, Rodriguez-
Labrada R et al (2014) Familial Alzheimer’s disease-associated
presenilin-1 alters cerebellar activity and calcium homeostasis. J Clin
Invest 124: 1552 – 1567
68. Guardia-Laguarta C, Area-Gomez E, Rub C, Liu Y, Magrane J, Becker D,
Voos W, Schon EA, Przedborski S (2014) Alpha-synuclein is localized to
mitochondria-associated ER membranes. J Neurosci 34: 249 – 259
69. Cali T, Ottolini D, Negro A, Brini M (2012) Alpha-synuclein controls mito-
chondrial calcium homeostasis by enhancing endoplasmic reticulum-
mitochondria interactions. J Biol Chem 287: 17914 – 17929
70. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-
Laguarta C, de Groof AJ, Madra M, Ikenouchi J, Umeda M, Bird TD, Stur-
ley SL et al (2012) Upregulated function of mitochondria-associated ER
membranes in Alzheimer disease. EMBO J 31: 4106 – 4123
71. Zampese E, Fasolato C, Kipanyula MJ, Bortolozzi M, Pozzan T, Pizzo P
(2011) Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria
interactions and Ca2+ cross-talk. Proc Natl Acad Sci USA 108:
2777 – 2782
72. Ottolini D, Cali T, Negro A, Brini M (2013) The Parkinson disease related
protein DJ-1 counteracts mitochondrial impairment induced by the
tumor suppressor protein p53 by enhancing endoplasmic reticulum-
mitochondria tethering. Hum Mol Genet 22: 2152 – 2168
73. Cali T, Ottolini D, Negro A, Brini M (2013) Enhanced parkin levels favor
ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell
bioenergetics. Biochim Biophys Acta 1832: 495 – 508
74. Guidato S, McLoughlin D, Grierson AJ, Miller CCJ (1998) Cyclin D2 inter-
acts with cdk-5 and modulates cellular cdk-5/p35 activity. J Neurochem
70: 492 – 500
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2016 The Authors EMBO reports
Radu Stoica et al ALS/FTD FUS disrupts ER–mitochondria associations EMBO reports
17
Published online: July 14, 2016 
